DK1154792T3 - Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans - Google Patents
Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvansInfo
- Publication number
- DK1154792T3 DK1154792T3 DK00906305T DK00906305T DK1154792T3 DK 1154792 T3 DK1154792 T3 DK 1154792T3 DK 00906305 T DK00906305 T DK 00906305T DK 00906305 T DK00906305 T DK 00906305T DK 1154792 T3 DK1154792 T3 DK 1154792T3
- Authority
- DK
- Denmark
- Prior art keywords
- sub
- adjuvant
- fatty acids
- monoglycerides
- vaccine formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
- 229930195729 fatty acid Natural products 0.000 title abstract 2
- 239000000194 fatty acid Substances 0.000 title abstract 2
- 150000004665 fatty acids Chemical class 0.000 title abstract 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229960002109 tuberculosis vaccine Drugs 0.000 title 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 2
- 201000008827 tuberculosis Diseases 0.000 abstract 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9900495A SE9900495D0 (sv) | 1999-02-12 | 1999-02-12 | Vaccine composition |
| PCT/EP2000/001046 WO2000047225A2 (en) | 1999-02-12 | 2000-02-09 | Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1154792T3 true DK1154792T3 (da) | 2007-02-12 |
Family
ID=20414469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00906305T DK1154792T3 (da) | 1999-02-12 | 2000-02-09 | Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6936260B1 (da) |
| EP (1) | EP1154792B1 (da) |
| AT (1) | ATE342065T1 (da) |
| AU (1) | AU769390B2 (da) |
| DE (1) | DE60031243T2 (da) |
| DK (1) | DK1154792T3 (da) |
| ES (1) | ES2275495T3 (da) |
| NZ (1) | NZ513130A (da) |
| SE (1) | SE9900495D0 (da) |
| WO (1) | WO2000047225A2 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
| DE60226175T2 (de) * | 2001-11-14 | 2009-07-09 | Novavax, Inc. | Mycobakterieller impfstoff |
| CA2469334C (en) * | 2001-12-11 | 2012-05-08 | Institut Pasteur | Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| CU23476A1 (es) * | 2004-01-29 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba |
| CA2596920C (en) * | 2005-01-28 | 2015-05-05 | North-West University | Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines |
| DK2144626T3 (da) * | 2007-04-12 | 2015-02-09 | Mico Bio Inc | Tuberkulosevaccine og fremgangsmåde til anvendelse af samme |
| CN102441162B (zh) * | 2010-10-04 | 2018-07-24 | 免疫产品美国股份有限公司 | 结核病的治疗和预防 |
| KR20140053887A (ko) * | 2011-04-20 | 2014-05-08 | 미코 바이오, 인크. | 면역 반응을 증진시키는 조성물 및 방법 |
| EP2620159A1 (en) * | 2012-01-24 | 2013-07-31 | Institut Pasteur | Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
| WO2018006939A1 (en) | 2016-07-05 | 2018-01-11 | Universidad De Zaragoza | Inactivated tuberculosis vaccine |
| WO2020115161A1 (en) | 2018-12-04 | 2020-06-11 | Sabiotec Spin-Off Sl | Immunostimulant for use against pathogens |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990014837A1 (en) * | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| WO1993006921A1 (en) | 1991-10-04 | 1993-04-15 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
| DK17093D0 (da) | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
| ATE318147T1 (de) * | 1996-03-25 | 2006-03-15 | Medarex Inc | Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen |
| SE9602280D0 (sv) | 1996-06-10 | 1996-06-10 | Pharmatrix Ab | Immunstimulerande lipidformulering |
-
1999
- 1999-02-12 SE SE9900495A patent/SE9900495D0/xx unknown
-
2000
- 2000-02-09 WO PCT/EP2000/001046 patent/WO2000047225A2/en not_active Ceased
- 2000-02-09 US US09/926,001 patent/US6936260B1/en not_active Expired - Fee Related
- 2000-02-09 ES ES00906305T patent/ES2275495T3/es not_active Expired - Lifetime
- 2000-02-09 EP EP00906305A patent/EP1154792B1/en not_active Expired - Lifetime
- 2000-02-09 AU AU28035/00A patent/AU769390B2/en not_active Ceased
- 2000-02-09 DE DE60031243T patent/DE60031243T2/de not_active Expired - Lifetime
- 2000-02-09 DK DK00906305T patent/DK1154792T3/da active
- 2000-02-09 NZ NZ513130A patent/NZ513130A/xx not_active IP Right Cessation
- 2000-02-09 AT AT00906305T patent/ATE342065T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE9900495D0 (sv) | 1999-02-12 |
| WO2000047225A2 (en) | 2000-08-17 |
| AU769390B2 (en) | 2004-01-22 |
| US6936260B1 (en) | 2005-08-30 |
| ATE342065T1 (de) | 2006-11-15 |
| ES2275495T3 (es) | 2007-06-16 |
| EP1154792B1 (en) | 2006-10-11 |
| DE60031243T2 (de) | 2007-05-24 |
| AU2803500A (en) | 2000-08-29 |
| NZ513130A (en) | 2003-01-31 |
| EP1154792A2 (en) | 2001-11-21 |
| WO2000047225A3 (en) | 2000-12-14 |
| DE60031243D1 (de) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0777490T3 (da) | Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans | |
| NO20002741D0 (no) | Vaksine-blandinger omfattende kitosan, for mukosal administrasjon | |
| MD1586G2 (ro) | Inducere a unui răspuns citotoxic T-limfocitar | |
| NO20052010L (no) | Immunogen sammensetning | |
| NO976060L (no) | Vaksiner mot hepatitt C | |
| PT865297E (pt) | Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes | |
| BRPI0000126B8 (pt) | composição de vacina, composição adjuvante e método de produção de uma composição de vacina | |
| BR9910296A (pt) | Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado | |
| DK0652773T3 (da) | Anvendelse af nor- og homo-galdesyrederivater somabsorptionsfremmende bestanddele i lægemidler | |
| EP2283858A3 (en) | West Nile Vaccine | |
| SE9900495D0 (sv) | Vaccine composition | |
| DE69634024D1 (de) | Adjuvans für vitale Impfstoffe | |
| BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
| GB9306731D0 (en) | Vaccines | |
| SE9602280D0 (sv) | Immunstimulerande lipidformulering | |
| PT792165E (pt) | Composicoes imunogenicas | |
| DK1150713T3 (da) | Vaccineformulering der omfatter monoglycerider eller fedtsyrer som adjuvans | |
| SE0100011D0 (sv) | Virus vaccine formulation | |
| BR9713296A (pt) | Processo para a preparação de derivados 2-amino-2-imidazolino, guanidino, e 2-amino-3,4,5,6-tetrahidro-pirimidina | |
| ES2145541T3 (es) | Nuevos seco-d-esteroides activos sobre el sistema cardiovascular, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| KR910002455A (ko) | 아크릴산 유도체를 함유하는 제약 조성물 및 의약으로서 이들의 사용 | |
| WO2002024147A3 (en) | Avian pneumovirus vaccine | |
| DK0617731T3 (da) | N-acyl-phosphatidylethanolamin som oxidationsbeskyttelsesmiddel |